Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Indianapolis IN and Boca Raton FL (U.S.A) – 15th May 2020. Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings Corp
Telix Pharmaceuticals (U.S.) Inc, a subsidiary of Telix Pharmaceuticals Limited is pleased to announce it has entered into a commercial distribution agreement with Boca Raton-based Pharmalogic Holdings Corp (‘Pharmalogic’) to provide nuclear pharmacy and logistics services to support Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
To read the full media release, please click here.